According to a market report by Lucintel, the future of the global chlorpheniramine maleate market looks promising with opportunities in the hospital pharmacy retail pharmacy, and online pharmacy markets. The global chlorpheniramine maleate market is expected to reach an estimated $606 billion by 2030 from $463 billion in 2024 at a CAGR of 4.6% from 2024 to 2030. The major drivers for this market are increase in the frequency of allergies and associated respiratory diseases such hives and allergic rhinitis, increase in pharmaceutical companies R&D expenditures to create more potent antihistaminic medications, as well as, developments in medication delivery technologies and pharmaceuticals.
A more than 150-page report to
understand trends, opportunity and
forecast in global chlorpheniramine maleate market to 2030 by dosage form (tablets, syrup, and
eye drops), application (allergy, hay fever (allergic rhinitis), common cold,
watery eyes, itchy throat/skin, anaphylactic shock, and urticaria), distribution
channel (hospital pharmacies, retail pharmacies, and online pharmacies), and
region (North America, Europe, Asia Pacific, and the Rest of the World).
Lucintel
forecasts that tablets will remain the larger segment over the forecast period
due to rise in prevalence of allergy and the easy availability of
chlorpheniramine maleate tablets.
APAC is
expected to witness highest growth over the forecast period due to increasing
prevalence of allergic diseases, increasing the number of leading market
players who produce chlorpheniramine maleate and raising consumer awareness
about allergies.
Download
sample by clicking on chlorpheniramine
maleate market.
Johnson
& Johnson, GlaxoSmithKline, Merck & Co, Zydus Lifesciences, Sun
Pharmaceutical Industries, Viatris, Alkem Laboratories are the major suppliers
in the chlorpheniramine maleate
market.
This unique research
report will enable you to make confident business decisions in this globally
competitive marketplace. For a detailed table of contents, contact Lucintel at
+1-972-636-5056 or write us at helpdesk@lucintel.com. To get access of more than 1000 reports at fraction of cost
visit Lucintel's Analytics
Dashboard.
About Lucintel
At Lucintel, we offer solutions for
you growth through game changer ideas and robust market &
unmet needs analysis. We are based in
Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20
years. We are quoted in several publications like the Wall Street Journal,
ZACKS, and the Financial Times.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. +1-972-636-5056
Explore Our Latest Publications
No comments:
Post a Comment